Gletmet-G2 Tablet PR contains a combination of Glimepiride 2 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. This combination therapy offers a complementary mechanism of action, effectively reducing fasting and postprandial blood glucose levels. Gletmet-G2 Tablet PR is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual oral hypoglycemic therapy. It is essential to monitor blood glucose levels regularly to optimize dosage and minimize the risk of hypoglycemia. The prolonged-release formulation ensures a steady release of active ingredients, enhancing patient compliance by reducing dosing frequency and mitigating gastrointestinal side effects commonly associated with Metformin. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to any component. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or during periods of acute illness. Gletmet-G2 Tablet PR should be used as part of a comprehensive diabetes management plan, including lifestyle modifications and regular medical supervision.